stockrow
Saturday 7 November 2026
Export TNYA’s income statement to Excel — free account
Tenaya Therapeutics, Inc.
TNYA Healthcare Biotechnology
- EPS
- +30.2%
- Free cash flow
- −13.2%
Quarter to September 2026, against a year earlier
0.36
0.04
+12.50%
Follow TNYA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 0.00 | 0.00 | 0.00 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (7.78) | (45.33) | (7.67) | |
P/B ratio |
— | 1.41 | 2.32 | 2.49 | |
Price to Tangible BV |
— | 1.41 | 2.32 | 2.49 | |
EV/Sales |
— | 0.00 | 0.00 | 0.00 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | (1.07) | (1.58) | (1.26) | |
EV/FCF |
— | (1.06) | (1.58) | (1.26) | |
Quick Ratio |
6.51 | 5.45 | 4.12 | 3.58 | |
Current Ratio |
6.84 | 5.75 | 4.52 | 3.78 | |
Net Debt/EBITDA |
5.31 | 4.42 | 1.84 | 3.48 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.69 | 1.00 | 0.08 | 0.93 | |
Capex/Depreciation |
(0.04) | (0.01) | (0.09) | 0.07 | |
Research and Development Expense of Revenue |
0.00% | 6,596.89% | 1,495.77% | 876.02% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 2,420.89% | 487.03% | 332.82% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 976.00% | 153.24% | 98.94% | |
Graham Net Nets |
— | 0.45 | 0.38 | 0.36 | |
Graham Number |
— | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
— | (68.12%) | (71.62%) | (82.30%) | |
Free Cash Flow Yield |
— | (43.19%) | (32.66%) | (40.28%) | |
Revenue per Share |
0.00 | 0.00 | 0.01 | 0.01 | |
Operating CF per Share |
(0.09) | (0.09) | (0.02) | (0.08) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.09) | (0.09) | (0.02) | (0.08) | |
Cash per Share |
0.66 | 0.37 | 0.36 | 0.30 | |
Shareholders Equity per Share |
0.81 | 0.49 | 0.32 | 0.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.81 | 0.49 | 0.32 | 0.24 | |
Free Cash Flow |
(14.01) | (19.24) | (3.71) | (17.66) | |
Working Capital |
90.15 | 79.78 | 66.99 | 52.21 | |
Capital Expenditures |
(0.07) | (0.01) | (0.16) | 0.03 | |
Net Current Asset Value |
81.93 | 67.68 | 61.88 | 48.85 | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.05 | 0.14 | (0.02) | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
4.37 | 3.49 | 3.10 | 3.25 | |
Average Assets |
133.43 | 139.51 | 107.85 | 90.83 | |
Average Common Equity |
108.06 | 112.79 | 84.62 | 68.69 |
Columns are period end dates · fundamentals updated 6 Nov 2026